Infection & Immunity
Infection & Immunity
Research in Infection & Immunity is translational and focused on common pathogenic mechanisms relevant for infection and immunity diseases on dynamics of pathogen transmission. Care will be multidisciplinary and includes standardized clinical/laboratory monitoring, collection of biological samples to create clinical, laboratory and immunology/microbiology databases and a biobank.
News uitklapper, klik om te openen
May 19: Genetic condition causes severe Staphylococcus aureus infections
Apr 25: New prediction model can help GP recognize sepsis in adults earlier
Apr 14: Antiretroviral drugs may impair cognitive function in people with HIV
Apr 12: UMC Utrecht to coordinate research on allergy risk assessment of ‘novel foods’
Mar 25: Corona self-tests more accurate when sample is taken from nose and throat
Mar 22: Aspirin may improve 3-month survival for patients critically ill with COVID-19
Overview news items
Annual review 2020
Annual review 2019
An overview of highlights and achievements in 2019.
Research themes uitklapper, klik om te openen
The strategic research program I&I aims for a national and international leading role in obtaining and disseminating knowledge and innovations in the field of inflammatory and infectious diseases and immune-mediated therapy. We aim to improve treatment in patients with difficult-to-manage infections, immune diseases or cancer. Our doctors and researchers closely collaborate to deliver high-quality care and cutting edge research, where possible together with patients. We ensure our knowledge and expertise by training talented people to become the future generation of experts.
Strategic program I&I is organized in four connected research themes. Each theme has distinct research lines, and clinicians, researchers and research groups are often active in more than one theme. The research themes are:
- preventing antimicrobial resistance;
- preventing inflammation;
- elucidating host-pathogen interactions;
- developing immune-mediated therapy and prevention.
Prof. dr. Marc Bonten, chairman strategic program I&I uitklapper, klik om te openen
Prof. dr. Marc Bonten is chairman of the strategic research program Infection & Immunity. He is actively involved in three research themes: antimicrobial resistance, alternatives for antibiotics, and infection dynamics and infection prevention. His focus is on ICU-acquired infections, mathematical modelling of antibiotic resistance, and vaccination.
Societal impact uitklapper, klik om te openen
Diseases resulting from failing immunity or infections (I&I diseases) constitute a major burden for humans, and sometimes require life-long treatment. Four of the 10 leading causes of death in the world are I&I diseases (WHO 2012). As are five of the top 20 most prevalent causes of moderate and severe disability in the world. Moreover, antibiotic-resistance is considered one of the major threats for human healthcare. To address the unmet medical need of I&I diseases the program will focus its efforts on 2 areas, which are prevention of infection and allergic and inflammatory diseases.
Ultimately, biomarker profiling to assess inflammatory signatures in individual patients will guide personalized treatment. Optimal treatment of patients with diseases resulting from failing immunity and/or infection requires a shift from typically organ-driven to personalized immune activation pattern-driven.
In the Spotlight: Lennie Derde MD, PhD on REMAP-CAP outcomes uitklapper, klik om te openen
Rapidly identifying drugs for treatment of severe COVID-19
Existing drugs helpful in COVID-19 IC patients
Intensive care physician Lennie Derde MD PhD, coordinator of the REMAP-CAP study in Europe, reflects on the outcomes of this adaptive platform trial so far.
The study has demonstrated that corticosteroids and interleukin-6 inhibitors tocilizumab and sarilumab improve clinical outcomes in critically ill COVID-19 patients; and that full dose anticoagulants improve outcomes in hospitalized, moderately ill patients. Several other drugs (full dose anticoagulants in critically ill patients, convalescent plasma, interleukin-1 inhibitor anakinra and antiplatelet therapy) did not improve outcomes, whereas lopinavir-ritonavir, hydroxychloroquine, or their combination may even worsen outcomes.
Education uitklapper, klik om te openen
Research collaborations uitklapper, klik om te openen
Research facilities uitklapper, klik om te openen
IMI-supported studies uitklapper, klik om te openen
The Innovative Medicines Initiative (IMI) is a partnership between the European Union and the European pharmaceutical industry. IMI facilitates open collaboration in research to advance the development of, and accelerate patient access to, personalized medicines for the health and wellbeing of all, especially in areas of unmet medical need. UMC Utrecht is playing a pivotal role in several of these large international projects in the fields of antimicrobial resistance, infection prevention and auto-inflammatory diseases.
Contact uitklapper, klik om te openen
3584 CX Utrecht
For request for internships (BSc/MSc), please feel free to contact a principal investigator (see above) that fits your research interest